Ligand Pharmaceuticals (LGND) Change in Taxes (2018 - 2026)

Ligand Pharmaceuticals has disclosed Change in Taxes across 9 years of filings, most recently posting -$695000.0 for Q1 2026.

• Change in Taxes for Q1 2026 came in at -$695000.0, down 107.46% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.0 million (down 161.93% YoY), and the FY2025 annual result was -$2.7 million, down 15.45% from the prior year.
• Change in Taxes came in at -$695000.0 for Q1 2026 at Ligand Pharmaceuticals, down from $955000.0 in the prior quarter.
• In the past five years, Change in Taxes ranged from a high of $12.0 million in Q1 2022 to a low of -$16.7 million in Q4 2022.
• The 5-year median for Change in Taxes is -$864000.0 (2025), against an average of -$321764.7.
• Peak annual rise in Change in Taxes reached 1018.75% in 2022, while the deepest fall reached 304.96% in 2022.
• Ligand Pharmaceuticals' Change in Taxes stood at -$16.7 million in 2022, then surged by 145.53% to $7.6 million in 2023, then slumped by 138.39% to -$2.9 million in 2024, then jumped by 132.74% to $955000.0 in 2025, then plunged by 172.77% to -$695000.0 in 2026.
• The last three Change in Taxes figures came in at -$695000.0 (Q1 2026), $955000.0 (Q4 2025), and -$864000.0 (Q3 2025), per Business Quant data.